Tekla Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Tekla Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$667K	Hold	131,990	–	–	0.03%	136
2023 Q1	$249K	Hold	131,990	–	–	0.01%	163
2022 Q4	$238K	Hold	131,990	–	–	0.01%	160
2022 Q3	$223K	Hold	131,990	–	–	0.01%	158
2022 Q2	$325K	Hold	131,990	–	–	0.01%	163
2022 Q1	$366K	Hold	131,990	–	–	0.01%	164
2021 Q4	$704K	Hold	131,990	–	–	0.02%	154
2021 Q3	$1.12M	Hold	131,990	–	–	0.04%	151
2021 Q2	$1.61M	Hold	131,990	–	–	0.05%	158
2021 Q1	$3.2M	Buy	+131,990	New	+$3.56M	0.11%	143

Other funds holding BDTX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tekla Capital Management's BDTX Position: Q2 2023 in Review

Tekla Capital Management held its Black Diamond Therapeutics (BDTX) position steady in Q2 2023 at 131,990 shares worth $667K. The position accounts for 0.03% of the portfolio, ranked #136.

Tekla Capital Management first reported a position in BDTX in Q1 2021 and has held it in 10 quarters since. The position peaked at $3.2M in Q1 2021. 74 funds tracked by Wall St. Rank hold BDTX as of Q2 2023.

Tekla Capital Management held 131,990 shares of Black Diamond Therapeutics worth $667K as of Q2 2023.
Tekla Capital Management left its Black Diamond Therapeutics share count unchanged in Q2 2023.
Black Diamond Therapeutics made up 0.03% of Tekla Capital Management's portfolio in Q2 2023, its #136 holding.
Tekla Capital Management first reported a position in Black Diamond Therapeutics in Q1 2021 and has held it in 10 quarters since.
Tekla Capital Management's Black Diamond Therapeutics position peaked at $3.2M in Q1 2021.
74 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.